Peptonic Medical provides Business and Product update- Broader product portfolio and continued expansion in the US
Peptonic Medical AB (publ) ("Peptonic" or the "Company") today provides an update on the Company’s product development, the commercial progress of its partnership with US-based Joylux Inc. ("Joylux"), and its efforts to broaden VagiVital into a stronger offering within women’s health and well-being. Several new products will be introduced during the autumn, including the Company’s first dietary supplement, while the partnership with Joylux continues to develop in the North American market.
During 2026, Peptonic has carried out extensive work to broaden its product portfolio and establish a clearer commercial platform for future growth. The strategy is based on two parallel revenue streams: international expansion through strategic partnerships, and the development and sale of a broader product portfolio under the Company’s own brands.
Partnership with Joylux Progressing According to Plan
The partnership with US-based Joylux, covering the United States, Canada, Mexico and the United Kingdom, has during the year progressed from the preparation phase to commercial sales. The first shipment was dispatched in June, after which the product was launched under Joylux’s own brand in North America and the United Kingdom.
According to Joylux, the market reception has been positive, and Peptonic has subsequently received additional orders under the partnership. The collaboration therefore represents important commercial validation of Peptonic’s technology and product platform and creates opportunities for gradually expanding distribution.
Joylux has established a significant presence in US retail and currently has products available through several major retail chains, including Walmart, Bloomingdale’s and Ulta Beauty. The product based on Peptonic’s technology is currently sold through Ulta Beauty, which operates approximately 1,500 stores in the United States, with the product currently available in around 400 locations.
Peptonic and Joylux share the ambition of gradually expanding the product’s reach in the US market. As part of this, the objective is to continuously introduce the product through additional US retail chains, thereby progressively reaching a broader consumer base. The existing presence at Ulta Beauty represents an important first step in this development.
New Product Category Broadens VagiVital
In parallel with its international expansion, Peptonic is significantly broadening its own product portfolio. During 2026, the Company has developed several new products that will gradually evolve VagiVital from a brand primarily focused on intimate health into a broader offering within women’s health, well-being and beauty.
Among the new products are VagiVital Intimate V Wipes, developed for gentle and convenient daily intimate care, and VagiVital Moisturizing Intimate Cream, a moisturizing intimate cream for external use. These products complement existing products such as VagiVital AktivGel and VagiVital Intimate Calming Gel and enable the Company to address a wider range of needs within women’s intimate self-care.
Dietary Supplements Open Up a New and Significantly Broader Market
An important step in the expansion of VagiVital is the launch of the Company’s first functional dietary supplement. The product, a daily dietary supplement in powder form, marks Peptonic’s entry into an entirely new product category with a significantly larger potential target group than the Company’s traditional intimate-care products.
The product has been developed with a focus on women’s daily well-being and is designed, among other things, to regulate hormonal balance, support the skin and mucous membranes, and contribute to energy and general well-being. The format is designed for daily use, and the product will become a natural part of VagiVital’s ambition to offer products that support women through different phases and needs in life.
The move into dietary supplements is strategically important for Peptonic. It enables the Company to enter the large and growing market for dietary supplements and functional nutrition, while also allowing VagiVital to address a significantly broader consumer group. At the same time, the product category creates opportunities for a high repurchase rate and recurring revenue through products intended for daily consumption.
The ambition is for the dietary supplement to become the first product in a broader offering within nutrition, health and well-being under the VagiVital brand. This creates a platform for future product launches in a category outside Peptonic’s historical core within intimate health, while targeting the same overall consumer group.
The new products are planned to be introduced gradually to the market during autumn 2026.
From Intimate Health to a Broader Platform for Women’s Health
The product launches form part of Peptonic’s long-term efforts to build a scalable platform within women’s health and well-being. By combining the Company’s established position and expertise within intimate health with new product categories and international distribution partners, Peptonic is creating opportunities to increase sales per customer, increase the share of repeat purchases and simultaneously reach new and significantly larger customer groups.
“We are now beginning to see the results of the strategic transformation carried out at Peptonic. Our partnership with Joylux has progressed from agreement to product launch and recurring orders, and our product is already available through hundreds of Ulta Beauty stores in the United States. Our ambition is to gradually expand distribution to additional US retail chains. At the same time, we are taking an important step with the launch of our first dietary supplement, which opens up an entirely new and significantly larger market for VagiVital. Together, these developments mean that we are moving from a company primarily focused on intimate care towards building a broader, internationally scalable platform within women’s health and well-being,” says Daniel Rudeklint, Interim CEO of Peptonic Medical AB.
Peptonic’s focus during the coming quarters will be on the commercialization of the new products, establishing dietary supplements as a new product category, continuing to develop the partnership with Joylux, and gradually expanding distribution in prioritized international markets. Our focus remains on the core business, while the Company is also evaluating long-term strategic opportunities in parallel, of which the acquisition of a shareholding in DGH International forms part.
For Further Information, Please Contact:
Daniel Rudeklint
Interim CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish women’s health company that develops and sells products within intimate self-care, health and well-being. The Company’s strategy is based on developing a broad product portfolio under its own brands, combined with international expansion through strategic distribution and brand partners. Peptonic Medical is listed on Spotlight Stock Market.